Researchers Find Common Measures of Immune Status, Inflammation Can Predict Mortality

A new collaborative study led by Cleveland Clinic and University Hospitals has found that commonly used clinical indicators of immune status and inflammation can predict mortality in the general population.

Published in JAMA Network Open, the study showed that lymphopenia (a condition characterized by low levels of a specific type of white blood cell, called lymphocytes) is associated with death due to heart disease, cancer and respiratory infections, including influenza and pneumonia. This relationship between lymphocyte levels and mortality was observed independent of age, other blood-based immune markers and clinical risk factors.

 

The research team was led by David Zidar, M.D., Ph.D., an interventional cardiologist and immunologist at UH Cleveland Medical Center and the Louis Stokes Cleveland Veteran Affairs Medical Center and Assistant Professor of Medicine at Case Western Reserve University School of Medicine, and Jarrod Dalton, Ph.D., epidemiologist in Cleveland Clinic’s Lerner Research Institute.

“Scientists have gone to great lengths and expense to develop novel biomarkers to identify people at the highest risk for death and disease,” said Dalton, senior author on the study. “Here we have taken a more pragmatic approach – investigating the predictive power of components of a patient’s white blood cell count, which is collected as part of routine blood work during standard health exams. The complete blood count test is convenient, inexpensive and, as our findings suggest, may be used to help physicians screen for and prevent disease and disease-related mortality.”

In this study, the team analyzed data from more than 31,000 participants who were followed over the course of 12 years as part of the National Health and Examination Survey (NHANES). NHANES is a program of the National Center for Health Statistics, part of the Centers for Disease Control and Prevention. Study participants were representative of the general United States adult population.

While the association between lymphopenia and reduced survival was observed independent of age and traditional clinical risk factors, the strength of the association increased when low lymphocyte levels presented in combination with other blood abnormalities, including elevated red blood cell distribution width (a measure of the body’s ability to generate and maintain a healthy population of red blood cells) and levels of C-reactive protein (an indicator of inflammation).

Applied in practice, the study’s findings suggest, for example, that a 65-year old with a high-risk profile based on these three immune indicators – lymphocyte count, red blood cell distribution width and C-reactive protein levels – is actually at greater mortality risk than someone who is a decade older and has a low-risk profile.

“With additional research, we will soon begin to understand the biologic processes that link these markers to disease, a critical step in the search for therapeutic targets,” said Sadeer Al-Kindi, M.D., a cardiologist at University Hospitals, clinical instructor at Case Western Reserve University School of Medicine and co-author on the study. “More immediately, we can certainly design systems that allow physicians to use pragmatic immune status indicators to ensure that the 10-20% of the general population at highest risk for mortality do not fall through the cracks of routine preventive care and early detection services.”

This study was a collaboration between members of the Clinical and Translational Science Collaborative (CTSC) of Cleveland, including researchers from Cleveland Clinic, University Hospitals, Case Western Reserve University, Louis Stokes Cleveland Veterans Affairs Medical Center and MetroHealth Medical Center. The CTSC Awards Program is administered through the National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH). This study was also supported by the National Institute of Aging, of the NIH.

 

 

0?ui=2&ik=834f2e870a&attid=0.1&permmsgid=msg-f:1651372243630056338&th=16eada4e65826392&view=fimg&sz=s0-l75-ft&attbid=ANGjdJ-n3ECD-RbBRG_XfTrjz8tAjrepBAIQXAHEdFE-wjsamCZVjDv-mQZaZX29sOsoipTiVYgG1YkR-wc-F7RLliDxVaF2g8ptzrUs8e2fUI3NuIinKMxx19jAOUs&disp=emb


Alicia Reale Cooney  |  Sr. Manager  |  Corporate Communications  |  Cleveland Clinic

9500 Euclid Ave. JJN4-01  |  Cleveland, OH 44195  | (216) 445-8324 |  (216) 408-7444 cell

0?ui=2&ik=834f2e870a&attid=0.2&permmsgid=msg-f:1651372243630056338&th=16eada4e65826392&view=fimg&sz=s0-l75-ft&attbid=ANGjdJ-oCs7A-fLZmGqP0drkY91iO136AYvZELYbV0RH0q0o8yEsve4BdZRra1oO0N8vWb8659y44xTkAxPV5DWPa9pthChu1wougwcPLbjGssKw5o1X1MWJ63HksnA&disp=emb   0?ui=2&ik=834f2e870a&attid=0.3&permmsgid=msg-f:1651372243630056338&th=16eada4e65826392&view=fimg&sz=s0-l75-ft&attbid=ANGjdJ9rCEzSJIoWM4YN5PDOJEC1TSgXPtydypmuaIbKM3qRURTrmRDBMIO062RrUAjnuBlNPAoNGApp_YaG95clPi9RVh-x4WKQCleHEHoCHHTLr_43FXt4M112Emw&disp=emb 0?ui=2&ik=834f2e870a&attid=0.4&permmsgid=msg-f:1651372243630056338&th=16eada4e65826392&view=fimg&sz=s0-l75-ft&attbid=ANGjdJ_B2Tbasi7d9THeV2rVuVC8L6dc_nIH4r6mqwnG4ZKV5qruwp8dFcbyYTNL7DQgqh6-l0G8-sE_sott3RAQygFGswym5XeJg6BGlaCe7OurSebhnOp4y7NBEmg&disp=emb0?ui=2&ik=834f2e870a&attid=0.5&permmsgid=msg-f:1651372243630056338&th=16eada4e65826392&view=fimg&sz=s0-l75-ft&attbid=ANGjdJ8L_wjJbAsUQ6e2cPmGzI1rqHXhAyxWLj_cktrZ7ddflVurzrFZevCANJiLdxkfh2paoKctiaWjCG6YnXPAiQTaMUkSivdydbu1HKHSx-s9tCx4JnucsIcqGZw&disp=emb

 

 

 

Please consider the environment before printing this e-mail

Cleveland Clinic is currently ranked as one of the nation’s top hospitals by U.S. News & World Report (2019-2020). Visit us online at http://www.clevelandclinic.org for a complete listing of our services, staff and locations. Confidentiality Note: This message is intended for use only by the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender immediately and destroy the material in its entirety, whether electronic or hard copy. Thank you.

Researchers Find Common Measures of Immune Status, Inflammation Can Predict Mortality

Researchers Find Common Measures of Immune Status, Inflammation Can Predict Mortality

Cleveland Clinic

1 week
8 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Up Next Autoplay
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
3 Views
Cancer-News 19 hours
HORIZON Study #ASH19 @RushMedical
HORIZON Study #ASH19 @RushMedical
Category: Multiple Myeloma
0 Views
ash 20 hours
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
0 Views
Cancer-News 20 hours
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
11 Views
ash 1 day
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
Category: Other
0 Views
ash 1 day
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
0 Views
ash 1 day
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 2 days
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
1 Views
ash 2 days
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 2 days
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 2 days